QuatRx Pharmaceuticals

QuatRx Pharmaceuticals Company is a pharmaceutical company focused on discovering and developing compounds in the endocrine and metabolic therapeutic areas. We currently have two clinical product candidates, ospemifene and fispemifene, which treat hormone deficiencies that result from aging in women and men. Ospemifene, our treatment for vulvar and vaginal atrophy, a common problem associated with estrogen deficiency in post-menopausal women, has completed Phase III and an NDA has been filed by our worldwide partner, Shionogi Inc. Fispemifene, our treatment for testosterone deficiency and other conditions in men, is in Phase II clinical testing. Our management team has extensive experience in pharmaceutical development, particularly in endocrine and cardiovascular therapies, having participated in over 60 clinical development programs in their careers. Our management team has contributed to over 30 programs involving approved drugs, ten of which reached annual sales in excess of $1 billion and include the world's best selling pharmaceutical product, Lipitor.